License, Acquisitions and Other Agreements - Acquisitions (Details) - USD ($)				1 Months Ended		3 Months Ended			6 Months Ended
	May 01, 2025	May 01, 2024	Jan. 07, 2024	Jun. 30, 2025	May 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	May 03, 2024
License and other agreements
Success-based milestone payments, based on regulatory approval				$ 185,000,000		$ 185,000,000			$ 185,000,000
Additional regulatory milestone payments				$ 60,000,000		60,000,000			60,000,000
Purchase Agreement, Knopp Amendment
License and other agreements
Common stock issued (shares)				3,588,688	1,872,874
Issuance of common shares, net of offering costs				$ 51,426,000	$ 65,981,000
Purchase Agreement, Knopp Amendment
License and other agreements
Number of securities called by warrants (shares)		294,195
Exercise price of warrants (in dollars per share)		$ 67.98
Warrants, fair value disclosure		$ 3,340,000
Purchase Agreement, Knopp Amendment
License and other agreements
Issuance of common shares, net of offering costs		$ 75,000,000
Fair value first anniversary of execution period		60 days
Purchase Agreement, Knopp Amendment, 2025 Additional Consideration
License and other agreements
Fair value first anniversary of execution period		60 days
Common shares issuable, value		$ 75,000,000
Forward contract, current
License and other agreements
Forward contract and derivative liability											$ 75,220,000
2024 Additional Consideration True-up | Level 3
License and other agreements
Change in fair value reported in other income (loss), net							$ (590,000)			$ (590,000)
Fair value											15,540,000
Forward Contract Liability, 2025 Addtional Consideration
License and other agreements
Common shares issuable, value (in shares)	3,588,688
Forward Contract Liability, 2025 Addtional Consideration | Level 3
License and other agreements
Change in fair value reported in other income (loss), net						21,894	(1,150,000)		20,074	(1,150,000)
Fair value		$ 63,940,000
2025 Additional Consideration True-up | Level 3
License and other agreements
Change in fair value reported in other income (loss), net							$ 1,630,000			$ 1,630,000
Fair value											$ 13,810,000
Change in fair value reported in other comprehensive loss						10,970,000			12,760,000
Forward Contract Liability, 2024 Additional Consideration | Level 3
License and other agreements
Change in fair value reported in other income (loss), net					$ 9,239,000
Pyramid Biosciences, Inc.
License and other agreements
Upfront payment of common shares, shares (in shares)			255,794,000
Upfront payment of common shares, value			$ 10,894,000
Research and development								$ 5,689,000
Common shares issuable (in shares)							98,129
Pyramid Biosciences, Inc. | Developmental And Regulatory Milestones, First Asset | Lead Asset
License and other agreements
Success-based payments				5,000,000		5,000,000			5,000,000
Pyramid Biosciences, Inc. | Developmental And Regulatory Milestones, Second Asset | Second Asset
License and other agreements
Success-based payments				30,000,000		30,000,000			30,000,000
Pyramid Biosciences, Inc. | Commercial Sales-Based Milestones
License and other agreements
Success-based payments				$ 40,000,000		$ 40,000,000			$ 40,000,000